A Randomized, Open-label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220643

Enrollment

536

Registered

2008-12-08

Start date

2009-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2/neu Positive Metastatic Breast Cancer

Interventions

Investigational study drug General name: GW572016 Drug / Investigational drug: Pharmacological classification code: 429, Other antineoplastic agents Dosage and administration: 1250 mg/day (when used

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: refer to ClinicalTrials.gov

Exclusion criteria

Exclusion criteria: refer to ClinicalTrials.gov

Design outcomes

Primary

Measure	Time frame
refer to ClinicalTrials.gov	—

Secondary

Measure	Time frame
refer to ClinicalTrials.gov	—

Countries

Asia, EU, North America, South America

Contacts

Public ContactKyosuke Yamauchi

Novartis Pharma. K.K.

rinshoshiken.toroku2@novartis.com+81-120-003-293

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026